Dr. Ren continued, "We appreciate the international recognition by our peers. For the next step, we intend to further advance 2ME2 development as part of our global drug development plan and strategy to leverage resources both in the US and China. We are currently exploring multiple strategies for the development of 2ME2 including possible partnership opportunities. We believe that the development of 2ME2 for autoimmune diseases fits well with our plan to build a robust product pipeline and to add value for our long term shareholders."
The article is entitled "2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation" and was authored by Gordon S. Duncan, Dirk Brenner, Michael W. Tusche, Anne Brustle, Christiane B. Knobbe, Andrew J. Elia, Thomas Mock, Mark R. Bray, Peter H. Krammer and Tak W. Mak. The article is available at http://www.pnas.org/content/early/2012/11/30/1215558110.
EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market. Its lead compound, ENMD-2076, a selective Aurora A and angiogenic kinase inhibitor for cancer, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently ini
|SOURCE EntreMed, Inc.|
Copyright©2012 PR Newswire.
All rights reserved